AMAG Pharma (AMAG) Misses Q1 EPS by 17c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raymond James Downgrades AMAG Pharmaceuticals (AMAG) to Market Perform
May 4, 2016 6:39 AM EDTRaymond James downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.
Shares of AMAG Pharmaceuticals closed at $22.03 yesterday.
... More